Copyright
©The Author(s) 2017.
World J Cardiol. Jul 26, 2017; 9(7): 583-593
Published online Jul 26, 2017. doi: 10.4330/wjc.v9.i7.583
Published online Jul 26, 2017. doi: 10.4330/wjc.v9.i7.583
Table 3 Current available guidelines addressing antiplatelet therapy for peripheral arterial disease
Class of recommendation | Guidelines |
Class Ia | Aspirin in daily doses of 75 to 325 mg or clopidogrel 75 mg/d is recommended to reduce the risk of MI, stroke, or vascular death in individuals with symptomatic atherosclerotic lower extremity PAD |
Class IIa | Antiplatelet therapy is reasonable to manage asymptomatic individuals with an ABI less than or equal to 0.90 to reduce the risk of MI, stroke, or vascular death |
Class IIb | Dual-antiplatelet therapy (aspirin and clopidogrel) may be reasonable to reduce the risk of limb-related events in patients with symptomatic PAD after lower extremity revascularization |
- Citation: Singh P, Harper Y, Oliphant CS, Morsy M, Skelton M, Askari R, Khouzam RN. Peripheral interventions and antiplatelet therapy: Role in current practice. World J Cardiol 2017; 9(7): 583-593
- URL: https://www.wjgnet.com/1949-8462/full/v9/i7/583.htm
- DOI: https://dx.doi.org/10.4330/wjc.v9.i7.583